The Testosterone Cardiovascular Warning Is Gone. Now What?

The TRAVERSE trial shifted what the evidence said about TRT and cardiovascular risk. The FDA label shifted in response. The combination of the two changed how providers approach TRT decisions in men with cardiovascular risk factors, and by 2026 the old warning had largely stopped dominating the conversation in a way it had for a decade.

This article is the short version of what changed on the label, what the new conversation looks like in practice, and what patients should know now. For the trial itself, see What the TRAVERSE Trial Actually Showed. For the broader framework on TRT decisions, see What TRT Actually Is.

What changed on the label

The 2015 testosterone label carried a specific cardiovascular warning language that had been added in response to the observational studies of the early 2010s. It told patients and providers that testosterone use might increase the risk of heart attack and stroke, and it was prominent enough that it shaped the entire prescribing culture.

After TRAVERSE published in 2023, the FDA reviewed the new evidence and updated the label in 2025. The update acknowledged that TRAVERSE had ruled out the specific MACE signal the old warning had been based on, and revised the cardiovascular language accordingly. The new label no longer carries the broad “may increase the risk of heart attack and stroke” language that the 2015 version had.

What the new label does still include:

Hematocrit monitoring. Testosterone increases red blood cell production. Elevated hematocrit is a real risk and the label still advises monitoring.

Thromboembolic event language. TRAVERSE showed a small but real increase in pulmonary embolism rates. The label addresses this.

Atrial fibrillation. The TRAVERSE AFib signal was added to the label as a cautionary note, especially for men with existing AFib or risk factors.

Prostate monitoring. Standard language about prostate cancer screening during TRT. The TRAVERSE trial did not show an increased prostate cancer signal, but the standard monitoring recommendations remain.

The net effect is a label that is more nuanced than the 2015 version. It tells the truth about the risks that are real without leaning on the one specific risk that turned out not to be supported.

What this means in practice

The label change has had a slow but real effect on provider behavior. A few things are different in 2026 than they were in 2022.

More endocrinologists and cardiologists are comfortable with TRT in men with stable cardiovascular disease. Before TRAVERSE, a history of heart attack or stable coronary disease was often a relative contraindication to TRT. After the label change, many providers will consider TRT in these patients if the symptoms and labs warrant it.

Primary care physicians are less reluctant. PCPs who had been deferring TRT decisions to specialists because of the cardiovascular warning are increasingly willing to prescribe or co-manage, especially in patients with clear symptomatic hypogonadism.

Online TRT clinics have updated their consent language. The old warning is no longer being read to new patients as a mandatory caveat in most reputable clinics.

Men researching TRT encounter a different information landscape. Search results now include coverage of TRAVERSE alongside the older warning articles. The conversation has shifted from “is TRT dangerous” to “what are the actual risks.”

What has not changed:

Men with known atrial fibrillation should still discuss TRT carefully with their cardiologist. The TRAVERSE AFib signal was real.

Men with clotting history or elevated hematocrit should still be monitored carefully. The thromboembolic signal was real.

Men with unstable heart disease should still approach TRT cautiously. TRAVERSE enrolled men with stable cardiovascular disease or risk factors, not men in active cardiac decompensation.

The change is not that TRT is now universally safe. It is that the specific warning that was driving the most hesitation is no longer the right framework, and the decision should be based on the actual risk profile of the individual patient.

The new conversation with your provider

If you are considering TRT and have cardiovascular risk factors, the conversation with your provider should sound different than it would have in 2022. A few questions that are more useful now than they were then:

What is my current hematocrit and will we monitor it quarterly? This is the single most important safety monitoring parameter on TRT. A good provider will have a clear answer about baseline and monitoring frequency.

Do I have any history of atrial fibrillation or risk factors for it? If yes, the conversation should include your cardiologist. If no, this is less of a concern than the 2015 warning would have suggested.

What is my clotting history? Previous DVT or PE, strong family history of clotting disorders, or known factor V Leiden all warrant extra caution and possibly a different delivery method or dose.

What is my delivery method going to be? TRAVERSE used testosterone gel. Injection is the most common method in modern practice. The safety data generalizes across methods for most outcomes, but if you have concerns, this is worth discussing.

What is the exit criterion if something changes? A provider who has a clear answer to “under what circumstances would we stop or reduce TRT” is a provider who is thinking about the decision as ongoing rather than one-time.

These are better questions than “is TRT dangerous.” The old question did not have a useful answer. The new questions do.

The men who benefit most from the change

The real beneficiaries of the label update are the men who had clinical hypogonadism and cardiovascular risk factors and were being denied TRT on the basis of the 2015 warning. These men were being undertreated for a condition with real symptoms because a warning based on weaker evidence was preventing them from accessing a therapy that the best available data now supports.

This is not a small group. A meaningful fraction of men over 50 with low testosterone also have cardiovascular risk factors, either from lifestyle, genetics, or the same metabolic syndrome that drove the low testosterone in the first place. Before TRAVERSE, these men were the hardest to treat. After the label change, they are increasingly able to have a real conversation about TRT with their providers.

If you are in this category and have been told in the last decade that you could not have TRT because of cardiovascular risk, it is worth revisiting the question with an up-to-date provider. The answer may still be no for your specific situation, but the answer is no longer automatic.

What to do if your provider is still using the old framework

If you are having a conversation with a provider who is still treating TRT as cardiovascular-hazardous in a way that does not match the current evidence, that is a signal about the provider’s information currency.

A few non-confrontational ways to handle it:

Bring a copy of the TRAVERSE paper to your visit. The NEJM paper is accessible and the primary finding is clear. Some providers will update their framework when they see the data directly.

Ask whether they have reviewed the 2025 label update. The question itself is informative. A provider who has reviewed the updated label will engage. A provider who has not will reveal that.

Consider whether this is the right provider for TRT management. Cardiovascular safety is one piece of TRT management, and a provider whose framework is a decade out of date on the most discussed question in the category is probably out of date on other things too. A second opinion is reasonable.

Find a provider who does TRT as a regular part of their practice. DPC physicians, hormone optimization specialists, and men’s health-focused clinics are more likely to be current on the literature than a generalist PCP who sees TRT rarely.

None of this means your current provider is wrong to be cautious. Individual risk factors matter and overly aggressive TRT prescribing is its own problem. But caution based on outdated information is a different thing from caution based on your specific situation.

The honest framing

TRT is not cardiovascular-neutral. It affects hematocrit, it has a real atrial fibrillation signal, it has a small thromboembolic signal. These are things that require monitoring and thoughtful management.

TRT is also not the cardiovascular hazard the 2015 warning implied. The best available evidence says it does not increase major adverse cardiovascular events in symptomatic hypogonadal men with stable cardiovascular disease or risk factors. The old warning was based on weaker data and was not supported when the rigorous trial was finally run.

The 2025 label update and the shift in provider behavior that followed are the correct response to that new evidence. If you were hesitating on TRT specifically because of the cardiovascular warning, the warning is not what it used to be and the decision is worth revisiting. The real risks are more specific, more manageable, and more worth having a real conversation with your provider about than the headline warning that dominated the conversation for a decade.

The new conversation is better because it is closer to the truth.